ÂÜÀòÂÒÂ×

Jennifer Richardson joined Dren Bio as our VP of Nonclinical Development in September 2021. Dr. Richardson most recently served as VP of Pharmacology and Toxicology for CytomX Therapeutics. During her time at CytomX, she led pharmacology, toxicology and bioanalysis functions in support of discovery research and product development for a portfolio of conditionally active antibodies. Prior to joining CytomX, Dr. Richardson held Director of Preclinical Development roles at ARCA Biopharma, Nuvelo, Abgenix and was a Senior Scientist at Millennium Pharmaceuticals. Dr. Richardson began her career at Harvard University Medical School and Dana Farber Cancer Institute after obtaining her PhD in Molecular Genetics from the University of Leicester and has been a Diplomat of the American Board of Toxicology since 2011.